HAMPTON, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1 (T cell immunoglobulin and mucin domain), which is upregulated in several cancers, including renal and ovarian carcinomas.
Poster details: Abstract # 2649 entitled "Development of an Antibody-drug Conjugate Targeting TIM-1 for the Treatment of Ovarian and Renal Cell Carcinoma" will be presented on Monday, April 7, 2014 from 1:00 p.m. to 5:00 p.m. PT in the session "New Antibodies and Antibody Drug Conjugates," Hall A-E, Poster Section 31, Poster Board Number 10. The lead author is Lawrence J. Thomas, PhD, DABT, ATS, Senior Director Preclinical Research and Development of Celldex Therapeutics.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
CONTACT: Sarah Cavanaugh Vice President of Investor Relations & Corporate Communications Celldex Therapeutics, Inc. (781) 433-3161 email@example.comSource:Celldex Therapeutics, Inc.